Search hospitals > Iowa > Iowa City
University of Iowa/Holden Comprehensive Cancer Center
Claim this profileIowa City, Iowa 52242
Global Leader in Parotid Gland Cancer
Global Leader in Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Relapse
Conducts research for Lymphoma
639 reported clinical trials
42 medical researchers
Summary
University of Iowa/Holden Comprehensive Cancer Center is a medical facility located in Iowa City, Iowa. This center is recognized for care of Parotid Gland Cancer, Cancer, Adult T-Cell Leukemia/Lymphoma, Relapse, Lymphoma and other specialties. University of Iowa/Holden Comprehensive Cancer Center is involved with conducting 639 clinical trials across 658 conditions. There are 42 research doctors associated with this hospital, such as David S. Dickens, Mariko Sato, Muhammad Furqan, and Yousef Zakharia, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
David S. DickensUniversity of Iowa/Holden Comprehensive Cancer Center8 years of reported clinical research
Expert in Brain Tumor
Expert in Cancer
64 reported clinical trials
123 drugs studied
Mariko SatoUniversity of Iowa/Holden Comprehensive Cancer Center8 years of reported clinical research
Expert in Brain Tumor
Expert in Cancer
49 reported clinical trials
95 drugs studied
Muhammad FurqanUniversity of Iowa Healthcare Cancer Services Quad Cities1 year of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
24 reported clinical trials
38 drugs studied
Yousef Zakharia, MDUniversity of Iowa Hospitals and Clinics6 years of reported clinical research
Studies Parotid Gland Cancer
Studies Renal Cell Carcinoma
21 reported clinical trials
46 drugs studied
Clinical Trials running at University of Iowa/Holden Comprehensive Cancer Center
Lymphoma
Esophageal cancer
Brain Tumor
Cancer
Ovarian Cancer
Acute Lymphoblastic Leukemia
Lung Cancer
Uterine Cancer
Breast Cancer
Adult T-Cell Leukemia/Lymphoma
Zanubrutinib
for Mantle Cell Lymphoma
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Recruiting2 awards Phase 310 criteria
Rituximab vs Mosunetuzumab
for Follicular Lymphoma
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Recruiting2 awards Phase 313 criteria
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Iowa/Holden Comprehensive Cancer Center?
Where is University of Iowa/Holden Comprehensive Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Iowa/Holden Comprehensive Cancer Center accept?
What awards or recognition has University of Iowa/Holden Comprehensive Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.